Efficacy of platelet-rich plasma and plasma for symptomatic treatment of knee osteoarthritis: a double-blinded placebo-controlled randomized clinical trial

Table 3 Summary of all related adverse events

Adverse events, n (%)	PRP (n = 20)	Plasma (n = 21)	Placebo (n = 21)	p-value
No	7 (35%)	16 (76%)	14 (67%)	0.025
Yes	13 (65%)	5 (24%)	7 (33%)
SAEs	0 (0%)	0 (0%)	0 (0%)	-
Deaths	0 (0%)	0 (0%)	0 (0%)	-
TEAEs, n (%)				0.914
Application site pain	8 (40%)	5 (24%)	5 (24%)
Index knee swelling	1 (5%)	0 (0%)	1 (5%)
Application site pain and index knee swelling	3 (15%)	0 (0%)	1 (5%)
Index knee stiffness	1 (5%)	0 (0%)	0 (0%)
Application site ecchymosis/Bleeding	0 (0%)	0 (0%)	0 (0%)
Pain intensity, n (%)				0.202
0 - Mild (0 to < 3)	6 (30%)	2 (10%)	4 (19%)
1 - Moderate (3 to 8)	7 (35%)	2 (10%)	1 (5%)
2 - Intense (> 8 to 10)	0 (0%)	1 (5%)	2 (10%)
Duration of pain in days, mean (SD)	2.1 ± 1.3	2.2 ± 1.1	3.6 ± 2.9	0.681

Abbreviations: PRP platelet-rich plasma, TEAEs treatment-emergent adverse events, SD standard deviation

ISSN: 1471-2474